

Erratum to: Inhibition of mTOR in carcinoid tumors

Simona Grozinsky-Glasberg · Marianne Pavel

Published online: 31 August 2012
© Springer-Verlag 2012

Erratum to: Targ Oncol DOI 10.1007/s11523-012-0225-x

Some errors occurred in the publication of this article. It should read:

Conflict of interest Dr. Simona Grozinsky-Glasberg serves as an invited speaker for Novartis and IPSEN.
Financial disclosures for Professor Marianne Pavel: 1. Grant - Institution - Novartis 2. Consulting fee or honorarium - Novartis, Pfizer, IPSEN 3. Support for travel to meetings for the study or other purposes - Novartis 4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like -none 5. Payment for writing or reviewing the manuscript - None 6. Provision of writing assistance, medicines, equipment, or administrative support- None.

In Table 1:
Correct references:
US-52 [26]
RADIANT-2 [27]

RAMSETE [29]
Correct values for RADIANT-2 Median PFS: 16.4 vs 11.3 (placebo) instead of 16.3 vs 11.

In the following sentence, the reference has been changed to 25 rather than 22:

Thirdly, it remains unclear in which treatment line everolimus should be used. So far, data from RADIANT-3 trial [25] did not show any differences in efficacy depending on previous use of chemotherapy, compared to the use of everolimus in therapy-naive patients.

The below reference has been corrected:

27. Pavel ME, Hainsworth JD, Baudin E et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. *Lancet* 378:2005–2012

The online version of the original article can be found at <http://dx.doi.org/10.1007/s11523-012-0225-x>.

S. Grozinsky-Glasberg
Neuroendocrine Tumor Unit, Endocrinology and Metabolism,
Service, Hadassah-Hebrew University Hospital,
P.O.B. 12000, 91120 Jerusalem, Israel
e-mail: simonag@hadassah.org.il

M. Pavel (✉)
Department of Gastroenterology and Hepatology,
Charité University Medicine Berlin,
Campus Virchow Klinikum, Augustenburger Platz 1,
13353 Berlin, Germany
e-mail: marianne.pavel@charite.de